Forte Biosciences (FBRX) Accumulated Expenses (2016 - 2026)
Forte Biosciences (FBRX) reported Accumulated Expenses of $6.28 million for Q2 2026, up 62.3% from $3.87 million a year earlier but down 40.6% from the prior quarter.
Powered by 
Analysis
Forte Biosciences (FBRX) Accumulated Expenses (2016 - 2026) Analysis & Trends
At the end of FY2025, Forte Biosciences posted Accumulated Expenses of $10.76 million, up 156.1% from FY2024.
- Accumulated Expenses has increased for four consecutive years, with a five-year compound annual growth rate of 60.2% (FY2020 to FY2025).
- By year, Accumulated Expenses came in at $4.2 million in FY2024 (+87.4%), $2.24 million in FY2023 (+10.7%), $2.03 million in FY2022 (+149.5%) and $812,000 in FY2021 (-20.3%).
- Five-year quarterly Accumulated Expenses spans a low of $680,000 in Q1 2022 and a high of $10.76 million in Q4 2025.
- Year over year, Accumulated Expenses has now increased in each of the last nine quarters, with growth averaging 99.3% over the last eight quarters.
- The high point for year-over-year Accumulated Expenses in five years was Q2 2023 (growth of 304.2%); the low point was Q2 2022 (a decline of 59.1%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $10.56 million (Q1 2026), $10.76 million (Q4 2025) and $7.5 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Forte Biosciences | 1.58 Bn | 1.38 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.28 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 10.76 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 4.01 Mn |
| Dec 31, 2024 | 4.20 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 2.24 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 3.29 Mn |
| Mar 31, 2023 | 2.42 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | 815,000.00 |
| Mar 31, 2022 | 680,000.00 |
| Dec 31, 2021 | 812,000.00 |
| Sep 30, 2021 | 1.41 Mn |
API Access
Forte Biosciences Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=FBRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "FBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=FBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();